PMVP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 9, 2025

News

TYPE

HEADLINE

FILED AT

8-K

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Oct 5, 2026

8-K

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering

Sep 1, 2026

8-K

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

Aug 31, 2026

8-K

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Progress on PYNNACLE Clinical Trial

Aug 14, 2026

8-K

PMV Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 5, 2026

8-K

PMV Pharmaceuticals Reports Q1 2026 Financial Results and Corporate Highlights

May 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 1, 2026

424B3

UPDATE TO PRIOR PROSPECTUS | Offering amount: $1,137,928,464 | Bank: Jefferies LLC

Aug 31, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: TD Cowen

Aug 31, 2026

424B3

UPDATED | ATM | Offering amount: $113,792,846.40 | Amount sold to date: $5,149,446.00

Nov 27, 2024

424B4

OFFERING | Shares amount: 11,765,000 | Share price: $18.00 | Offering amount: $211,770,000.00

Sep 25, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 6, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 28, 2025

S-3

SHELF | ATM | Offering amount: $200,000,000.00 EFFECTIVE

Nov 20, 2024

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Aug 14, 2024

SC TO-I

Form SC TO-I - Tender offer statement by Issuer

Jul 16, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 24, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 22, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 25, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 25, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 24, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Eckler Matthew Joseph (Reporting)

Oct 5, 2026

Eckler Matthew Joseph (Reporting)

Oct 5, 2026

SCHEDULE 13G

Samsara BioCapital, L.P. (Filed by)

Sep 15, 2026

SCHEDULE 13G/A

Sio Capital Management, LLC (Filed by)

Jul 28, 2026

SCHEDULE 13G/A

ArrowMark Colorado Holdings LLC (Filed by)

Jul 10, 2026

Stelzer Laurie (Reporting)

Jun 5, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 29, 2024

CORRESP

Form CORRESP - Correspondence

Nov 25, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 25, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 1, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 25, 2020

CORRESP

Form CORRESP - Correspondence

Sep 22, 2020

PMV Pharmaceuticals, Inc. PMVP · SEC Filings